Table 1.

Demographic characteristics of enrolled patients

	Group 1 −rUTI/+VET (n=30)	Group 2 +rUTI/+VET (n=20)	Group 3 +rUTI/−VET (n=20)
Age [mean (SD)]	75.4 (7.3)	74.3 (7.1)	71.9 (8.5)
BMI [mean (SD)]	27.0 (4.0)	29.7 (7.0)	29.8 (5.2)
Recurrent UTI (% yes)	0	100	100
VET at enrollment (% yes)	100	100	0
Frequency of VET use [median (range)]	2 (1–3)	2 (2–3)	--
Most recent uropathogen [n(%)]
E. coli	--	11 (55)	5 (25)
K. pneumoniae	--	3 (15)	4 (20)
Enterobacter spp	--	0 (0)	2 (10)
Other*	--	6 (30)	9 (45)
Other rUTI prophylactic agents	0	15 (75)	11 (55)
D-mannose	0	13 (65)	8 (40)
Methenamine hippurate	0	6 (30)	3 (15)
Vitamin C	0	10 (50)	6 (30)
Cranberry supplementation	0	4 (20)	2 (10)

Group 1: no history of recurrent urinary tract infection (rUTI), on vaginal estrogen therapy (VET). Group 2: history of rUTI, on VET. Group 3: history of rUTI, not on VET. BMI, body mass index. No difference between groups in age or BMI (p>0.05 for both). No difference between Group 1 and 2 in overall use of other rUTI prophylactic agents or specific agents (D-mannose, methenamine hippurate, vitamin C, cranberry, p>0.05 for all).

^*includes Enterococcus spp, Group B streptococcus, actinobactim, coagulase negative staphylococcus, Aerococcus, salmonella, pseudomonas aerongenes, streptococcus viridans